Background: To assess the predictive value of polymorphism in nine genes, primarily thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT), which relates to 5-fluorouracil (5-FU) metabolism, for toxicity in patients treated with oral uracil/tegafur (UFT) plus leucovorin (LV).
introduction 5-Fluorouracil (5-FU) has been widely used since the 1960s as first-line chemotherapy for colorectal cancer both in the adjuvant and palliative setting and remains the backbone of many combination chemotherapy regimens [1] [2] [3] . The composition of uracil/tegafur (UFT) is 1-(tetrahydrofuryl)-5-fluorouracil (tegafur [FT] ) and uracil in a molar ratio of 1 : 4. The coadministration of uracil enhances both the concentration of 5-FU in tumors and the resulting antitumor activity of FT [4] . The results of the National Surgical Adjuvant Breast and Bowel Project Protocol C-06 have demonstrated that oral UFT + leucovorin (LV) achieved similar disease-free survival and overall survival when compared with i.v. 5-FU + LV (Roswell Park regimen) and was associated with improved convenience of care [5, 6] .
It is widely recognized that apart from confounding environmental and physiological factors, inherited variability in drug-metabolizing enzymes, drug transporters, and drug targets play an important role in the variability of treatment outcomes. Drug-related toxicity reflects almost exclusively to nontumor tissue, and therefore, inherited polymorphisms can play a central role in determining toxicity. As major toxicity remains the mainstay limitation to adequate dosing, the ability to predict toxicity before the administration of chemotherapy and to provide individualized treatment would likely result in improved outcome.
Therefore, we investigated prospectively the predictive value of 22 polymorphisms within nine genes, which relate to 5-FU metabolism, for toxicity in patients with colorectal cancer receiving oral UFT + LV. 
patients and methods

treatment and toxicity assessment
We conducted chemotherapy in all eligible patients between 21 and 42 days after surgery. UFT was administered at a dose of 300 mgÁm 2 /day, and LV was administered at a dose of 75 mg/day given orally on days 1-28, followed by a 7-day rest, repeated every 35 days per one cycle up to five cycles. The doses of both UFT and LV were divided into three doses administered 8 h apart and taken together, along with water. Patients were instructed to avoid food consumption between 1 h before and 1 h after each dose. Prophylactic administration of antigastrointestinal mucositis (lafutidine, H 2 -receptor blocker) at standard doses was routinely used. Toxicity grade was recorded according to the National Cancer Institute Common Toxicity Criteria, version 2.0. Physical examination, a full blood count, and serum chemistry were done before every treatment course. If the absolute neutrophil count was <1000/mm 3 , the platelet count was under 7.5 · 10 4 mm 3 , or if grade 2 or greater nonhematological toxicity was occurred, then treatment was interrupted until the recovery. UFT and LV were resumed at the same doses when the toxicity had resolved.
Protocol-specified dose reductions and delays were based on previous cycle toxicity, utilizing both hematological nadirs and hematological/ biochemical parameters on the day following treatment. In this study, the UFT dose was reduced by 100 mg/day when grade 3 or greater toxicity (when grade 2 or greater toxicity in the cases of thrombocytopenia and hyperbilirubinemia) occurred in the previous treatment cycle, but the LV dose remained at 75 mg/day.
Treatment was discontinued for unacceptable toxicity, a delay of >42 days in instituting the next cycle of treatment or at the patients' request.
genotyping
Whole blood samples were obtained from the participants before initiation of the treatment. Gene polymorphisms were analyzed on DNA extracted from 9 ml whole blood (Paxgene Blood DNA Kit; PreAnalytiX GmbH, Hombrechtikon, Switzerland) ( Table 1 ). The assays for most polymorphisms were carried out as described previously by the restriction fragment length polymorphism method [7] [8] [9] [10] [11] [12] . For DPD 85T>C (*9A), DPD 1627A>G (*5), MTRR 66A>G, and orotate phosphoribosyltransferase (OPRT) 638G>C, we used the Assay-on-Demandä SNP genotyping product (Applied Biosystems, Foster City, CA). UGT1A1 polymorphisms were analyzed partially as described previously [12] . Briefly, first, exon 1 of UGT1A was amplified with first amplification primers. Then, for UGT1A1 240_39insTA (*28), the PCR products were amplified with second amplification primers and sequenced. For UGT1A1 211G>A (*6), 1813C>T (*1B), and 23279T>G (*60), first PCR products were used for detection using MGB probes. DPD 2194G>A (*6) and DPD IVS14 + 1G>A (*2A), and CYP2A6 248T>G (*9) and CYP2A6 670T>C (*11) were detected by the same method using primer and MGB probes. For CYP2A6 248T>G (*9) and CYP2A6670T>C (*11), the specific regions of CYP2A6 including each polymorphism were amplified [13, 14] and detected by real-time PCR. For CYP2A6 1412T>C (*7), DNA were amplified and were sequenced [15] . Laboratory personnel (AO) were blinded to the case status of the study participants during the entire genotyping process. All clinicians were unaware of the genotyping results.
statistics
The primary end point of the study was to investigate the relationships between thymidylate synthase (TS) or OPRT polymorphisms and toxicity. Genotype frequencies for TS variable number of tandem repeats (VNTR) (2R/2R) and OPRT638G>C (C/C genotype) were 0.046 and 0.087, respectively, in Japanese population, as previously reported [16] . Therefore, we considered that at least 100 patients were needed to investigate the association between the genotypes of interest and toxicity. This sample size was sufficient to detect the differences with 90% power at the two-sided 5% level of significance, assuming 66.6% incidence of severe diarrhea for TS VNTR (2R/2R) and 100% incidence of severe diarrhea for OPRT 638G>C (C/C) genotype as previously reported [16] .
Fisher's exact test was used to compare the genotype distribution with that expected by the Hardy-Weinberg equilibrium. The association between the genotype and toxicity was evaluated by Fisher's exact test. The worst toxicity grade during treatment cycles was used for association analysis. For continuous variables, the nonparametric Kruskal-Wallis test was used. In multivariate analysis, the relation with toxic effects was examined by logistic regression including genotypes of interest, age (<65 or ‡65), gender (male or female), and performance status (0 or 1). Statistical significance was defined as P < 0.05. SAS software version 9.1.3 and JMP software version 7.0.1 (SAS Institute, Inc., Cary, NC) were used for statistical analyses.
results
distribution of allele frequencies
None of the all analyzed polymorphisms showed any deviation from the Hardy-Weinberg equilibrium. Allele frequencies of Deletion (*4), 21013A>G (*1D), 248T>G (*9), 670T>C (*11), 1412T>C (*7)
SNP, single-nucleotide polymorphism; UTR, untranslated region.
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patient characteristics and overall toxicity
Baseline characteristics of 99 patients were as follows: mean age, 65 years (range 30-80 years); male and female, 58 and 41 patients; colon and rectum, 59 and 40 patients; stages II and III, 51 and 48 patients; and performance status zero and one, 72 and 27 patients, respectively. The patients received a total of 444 treatment cycles (median, 5 cycles; range 0.1-5 cycles). Toxicity is summarized, according to the worst grade per patient during all treatment cycles, in Table 2 . There were no treatment-related deaths. The most common type of toxicity was fatigue. The most common type of hematological toxicity was anemia, which was generally mild. Six patients each had grade 3 diarrhea or anorexia.
Treatment was discontinued in 18 of the 99 patients, because of toxicity in 14, pneumonia in 1, tumor recurrence in 1, and patient complaints in 2. The main type of toxicity in the 14 patients was grade 3 diarrhea with grade 2-3 anorexia in 5, grade 2-3 anorexia in 2, grade 2-3 liver injury in 2, grade 3 jaundice in 2, grade 2 rash in 1, grade 2 diarrhea in 1, and grade 3 muscle pain in 1. Nine of these 14 patients received UFT alone after the toxic effects had resolved. The other five patients refused further chemotherapy.
univariate association analysis between genotypes and toxic effects Initially, we analyzed the associations between each polymorphism and the frequency of both grade 2 or greater and grade 3 or greater toxic effects using Fisher's exact test (supplemental Table S1 , available at Annals of Oncology online). Toxic effects of ‡10% incidence in grade 2 or greater were analyzed because severe adverse events had relatively low incidence in this study cohort.
The MTRR 66GG genotype was associated with a higher risk for grade 2 or greater stomatitis [3 (30%) of 10 in G/G, 8 (22%) of 37 in A/G, and 4 (8%) of 52 in A/A genotype, P = 0.046].
The OPRT 638G>C polymorphism was statistically significantly associated with higher risk for grade 3 diarrhea [2 (50%) of 4 in C/ C, 1 (3.4%) of 29 in G/C, and 3(4.5%) of 66 in G/G wild type, P = 0.031] and was also statistically significantly associated with higher risk for grade 2-3 anorexia [2 (50%) of 4 in C/C, 1 (3%) of 29 in G/ C, and 7 (11%) of 66 in G/G, P = 0.035].
The incidence of grade 2-4 fatigue was significantly higher in MTHFR 1298CC genotype [1 (33%)
The polymorphisms of OPRT 638G>C, UGT1A1 diplotype (*6 or *28), and CYP2A6 variant were statistically significantly associated with higher risk of grade 2-3 hyperbilirubinemia (P = 0.013, <0.001, and 0.039, respectively).
Neither of four TS nor three DPD polymorphisms was associated with any toxicity. Polymorphism of MTR 2765A>G, SLC19A1 80G>A, or MTHFR 677C>T was also not associated with an increased risk of developing any toxicity.
multivariate analysis and time to onset of severe toxicity
Using multivariate logistic analysis including age, gender, and performance status, MTRR 66A>G was found to be a significant risk factor for grade 2 or greater stomatitis [OR (odds ratio) (Table 3) . Only OPRT polymorphism was found to be a statistically significant risk factor for any grade 3 adverse events, with an OR of 17.60 (95% CI 1.58-195.89, P = 0.02) in C/C genotype, when multivariate logistic analysis was carried out. In addition, a significant difference was observed in the time to onset of severe toxicity according to OPRT genotype (P < 0.0002, logrank test; supplemental Figure S1 , available at Annals of Oncology online).
For grade 2 or greater hyperbilirubinemia, UGT1A1 diplotypes (2/2, +/2, and +/+) were included in the final model because UGT1A1 diplotype was selected as statistically significant risk factor in the multivariate model with stepwise regression (P values to both enter and remove variables were settled at <0.05) including OPRT 638G>C (GC+CC versus GG), UGT1A1 diplotype (+/2 and +/+ versus 2/2), and CYP2A6 variant polymorphisms (variant versus wild) with age, gender, and performance status. Thus, UGT1A1 diplotypes were statistically significantly associated with grade 2 or greater hyperbilirubinemia (OR 38.76 for homozygotes and double heterozygotes of UGT1A1*6 or *28 compared with wild type, P = 0.0008) ( Table 3 ).
UGT1A1 genotypes and bilirubin level
The bilirubin level before treatment varied as a function of the UGT1A1 diplotype with the homozygous and double heterozygous type of *6 or *28 being associated with higher levels of bilirubin (P = 0.042). The average bilirubin level increased from 0.70 to 1.80 mg/dl in UGT1A1 homozygous and double heterozygous type, while it increased from 0.59 to 1.28 mg/dl in UGT1A1 heterozygous type and from 0.48 to 0.97 mg/dl in UGT1A1 wild type. Figure 1 shows the differences between baseline and maximum value in bilirubin levels according to UGT1A1 diplotype (P = 0.0018).
discussion
We have shown that OPRT polymorphism predicts severe toxicity, especially grade 3 diarrhea, in patients receiving UFT + LV. To the best of our knowledge, this is the first prospective study to investigate the relationship between OPRT polymorphism and toxicity during UFT + LV therapy. Polymorphisms of UGT1A1 diplotype (*6 or *28) were associated with hyperbilirubinemia. Of note is the germline TS polymorphisms did not predict for toxicity to UFT/LV therapy in this study cohort.
The impact of OPRT homozygous genotype (C/C) was the most significant in terms of any severe adverse event, especially grade 3 diarrhea, which was also confirmed by multivariate logistic analysis. Our results were similar to the previous retrospective study that showed OPRT polymorphisms to be associated with severe toxicity among colorectal cancer patients who received 5-FU chemotherapy [16] . The mechanism of gastrointestinal toxicity was reported to be due to the incororation of 5-FU into RNA (F-RNA), not the inhibition of the biosynthesis of dTMP through conversion of 5-FU to FdUMP [17] . Hence, higher OPRT activity, leading to elevated levels of F-RNA in the small intestine after the administration of UFT + LV, could be reasonably expected to increase the likelihood of severe diarrhea in patients with the homozygous genotype.
Although a number of studies have investigated the effect of TS VNTR genotypes on toxicity in patients treated with 5-FU, the results are conflicting [18] [19] [20] . Two studies investigated the role of TS VNTR genotype on toxicity and both showed an inverse relationship between the numbers of tandem repeats in TS VNTR and the severity of toxicity experienced by patients [18, 21] . This association, however, did not remain significant following the consideration of the G>C single-nucleotide polymorphism in 5# untranslated region (UTR) [22, 23] . The TS 3# UTR polymorphism has not been as extensively studied as TS VNTR, with few clinical studies investigating the association between the 3# UTR polymorphism and toxicity original article Annals of Oncology from fluoropyrimidine-based therapies [21] . No relationship was observed, which is consistent with our results. A deficiency of DPD is associated with severe toxicity after the administration of 5-FU. In DPD-deficient patients, 5-FU clearance is dramatically reduced and standard doses of 5-FU cause excessive toxicity [24, 25] . The most frequent mutation in patients with partial or complete DPD deficiency could be a G-to-A point mutation within the 5#-splicing site of intron 14 (exon 14-skipping mutation, IVS14 + 1G>A) [26] . This mutation was commonly detected in 24%-28% of all patients suffering from severe 5-FU toxicity, whereas the frequency of the mutant allele is actually 0% in the Japanese population [26, 27] , which agrees with our study. Neither DPD*9A nor DPD*6 polymorphism was associated with toxicity in our study, perhaps because they did not correlate with low DPD activity [28, 29] . There is little knowledge about the relation between the toxicity and DPD*5 polymorphism. Our results also showed no obvious associations between DPD*5 polymorphism and the various toxicity. On the contrary, a previous report by Zang et al. [30] showed that patients with DPD*5 variant homozygous type were more likely to have moderate-to-severe nausea and vomiting and leukopenia compared with those with DPD*5 wild or heterozygous type, perhaps because DPD*5 homozygous type could result in the lower DPD enzyme activity and 5-FU dysmetabolism. However, other previous reports showed that DPD*5 polymorphism was not associated with the DPD protein level [29, 31] . Further study on the correlation between DPD*5 polymorphism, the DPD protein level, and the toxicity is needed.
MTHFR polymorphisms may augment toxic side-effects of 5-FU by increasing intracellular concentrations of 5,10-methylenetetrahydrofolate and enhancing the formation and stability of ternary inhibitory complex [19, 20] . Regarding the MTHFR 677C>T polymorphism, the wild type (C/C) was associated with moderate-to-severe toxicity compared with MTHFR heterozygous (C/T) and variant type (T/T) in our study using univariate analysis, but this is a invert relationship. Only a few studies have analyzed the role of MTHFR 677C>T polymorphism on toxic side-effects after fluoropyrimidine therapy in colorectal cancer but the results have been inconsistent and inconclusive [19, 32, 33] . Regarding the MTHFR 1298A>C polymorphism, MTHFR homozygous genotype (C/C) in advanced colorectal cancer patients was correlated with an increased risk of developing severe adverse events after 5-FU-based chemotherapy [33] . However, we found only a nonsignificant trend association for grade 2 or greater fatigue in the multivariate analysis.
Polymorphisms in MTR, MTRR, and SLC19A1 were associated with serum homocysteine concentration, respectively [10, 11, 34] , and decreasing homocysteine levels may lead to a reduction of severe toxicity [35] . We did find a correlation between MTRR 66A>G polymorphisms and grade 2 or greater stomatitis, but not between MTR or SLC19A1 polymorphism and any toxic effects. However, this association may conflict with MTRR enzymatic function as previously reported [34] , and therefore, the predictive value for toxicity is unclear.
CYP2A6 is a rate-limiting enzyme in activating tegafur (FT) to 5-FU [36] , although many enzymes are known to be involved in the metabolism of FT. Several polymorphisms of CYP2A6 are known and may cause decreased expression level and enzymic activity [7, 14, 15] . Patients lacking CYP2A6 activity are expected to show a poor metabolic phenotype upon medication with FT. However, we did not find a clear correlation between the polymorphisms and toxicity.
Patients with UGT1A1 diplotype (homozygous and double heterozygous type of *6 or *28) were more likely to have hyperbilirubinemia than those with the wild or the heterozygous type in our study. Furthermore, we found for the first time that UFT + LV-induced increase in bilirubin levels was significantly higher in patients with the homozygous and double heterozygous type of either UGT1A1*6 or *28 compared with heterozygous and wild type. This was consistent with a previous report showing significance of UGT1A1 diplotype and the correlation between diplotype and serum bilirubin levels, a parameter of in vivo UGT1A1 activity, in irinotecantreated Japanese cancer patients [37] [38] [39] . Patients who receive chemotherapy for malignant tumor sometimes have mild and transient unconjugated hyperbilirubinemia with no evidence of liver dysfunction. We do not know the cause of this hyperbilirubinemia, although we know that the inherited moderate unconjugated hyperbilirubinemia of Gilbert syndrome is caused by mutations of UGT1A1 [40] [41] [42] . Chemotherapeutic agents may induce hyperbilirubinemia as do the agents that inhibit DNA and RNA synthesis [43] and that reduce the amount of bilirubin uridine diphosphateglucuronosyltransferase synthesized in hepatocytes. Patients with UGT1A1 mutations may produce a less efficient form of the enzyme, and they may show a transient increase of unconjugated bilirubin.
In conclusion, our results demonstrated that OPRT polymorphism predicts toxicity, especially grade 3 or greater diarrhea, whereas TS does not. UGT1A1 polymorphism seems Figure 1 . Uracil/tegafur/leucovorin-induced increase in bilirubin levels according to polymorphisms in UGT1A1 diplotype. 2/2, *1/*1, *1/*60; +/2, *1/*6, *1/*28, *6/*60, *28/*60; +/+, *6/*6, *6/*28.
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to be a risk factor for hyperbilirubinemia related to UFT + LV. Although the data suggest that we can identify some patients, who require close monitoring or adjustment of UFT + LV dosage, the relationship between polymorphisms and the toxicity of fluorouracil-based therapy such as UFT + LV should be confirmed in further studies. 
